BioSpace News Archive

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2023, and provided a business update.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.

Cue Health announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to develop a Flu A/B, RSV, and COVID-19 molecular multiplex test for both over-the-counter and point-of-care use.

The global glaucoma market size was estimated at USD 8.06 billion in 2022 and it is projected to hit around USD 12.69 billion by 2032, growing at a CAGR of 4.64% from 2023 to 2032. The glaucoma market in the United States was accounted for USD 3 million in 2022.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis and obesity, announced that it has granted as of August 1, 2023 an equity inducement award to one new employee under the terms of the 2022 Employment Inducement Award Plan.

Piramal Pharma Limited, announced its consolidated results for the first quarter ended 30th June 2023.

Mesoblast Limited announced that the US Food and Drug Administration has provided a complete response to its Biologics License Application resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease and requires more data to support marketing approval.

PTC Therapeutics, Inc. announced a corporate update and financial results for the second quarter ending June 30, 2023.

Azenta, Inc. will announce fiscal third quarter 2023 earnings which ended on June 30, 2023 on Tuesday August 8, 2023 after the market closes.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2023.